Test Price
2,800 AED✅ Home Collection Available
EIF2AK3 Gene Sequencing Test for Wolcott‑Rallison Syndrome in UAE | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل جين EIF2AK3 (متلازمة والكوت‑راليسون) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Clinically Guaranteed – 99.9% Diagnostic Sensitivity using ISO‑certified processing.
- Premium Logistics: Paid hospital‑grade home collection via ISO‑certified cold‑chain transport and VIP mobile phlebotomy, 8 AM–11 PM.
- Clinical Guidance: Complimentary telephonic post‑test interpretation of results with a DHA‑licensed genetic counsellor.
- Insurance: Direct billing eligibility verification through WhatsApp at +971 54 548 8731.
Clinical Overview
The EIF2AK3 NGS test provides a definitive molecular diagnosis for Wolcott‑Rallison syndrome (neonatal diabetes, epiphyseal dysplasia, hepatic/renal failure). It sequences the entire coding region of the EIF2AK3 gene using Next‑Generation Sequencing, delivering a sensitivity of 99.9% and requiring only a simple blood sample or DNA FTA card.
يقدم التحليل تشخيصًا جزيئيًا قاطعًا لمتلازمة والكوت‑راليسون عبر تقنية التسلسل الجيني الكامل لجين EIF2AK3، بدقة فائقة وباستخدام عينة دم أو بطاقة FTA.
| Feature | Our EIF2AK3 NGS Test | Whole Exome Sequencing (WES) |
|---|---|---|
| Method | Single‑gene NGS (full EIF2AK3 coverage) | Simultaneous protein‑coding regions of all genes |
| Diagnostic Precision | 99.9% sensitivity for missense, nonsense, indels, and splice‑site variants | ~95% sensitivity; may miss deep intronic or regulatory mutations |
| Turnaround Time | 3–4 weeks | 8–12 weeks |
| Cost (AED) | 2,800 | ≈5,000–7,000 |
| Clinical Interference | No incidental findings – only EIF2AK3 is analysed | High rate of incidental/secondary findings |
Physician Insight & Safety Protocol
“As a DHA-licensed clinical pathologist, I urge families to interpret this test together with a paediatric endocrinologist or clinical geneticist. A positive result confirms the diagnosis, but the clinical picture—neonatal diabetes after 6 weeks, spondyloepiphyseal dysplasia, and recurrent hepatic crises—remains the cornerstone of management. Negative results do not exclude the syndrome if a deep intronic variant lies outside our targeted capture; further biochemical testing is essential.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
Medication Warning: Do not discontinue prescribed insulin, ursodeoxycholic acid, or any other medication without consulting your managing consultant. Genetic testing informs, but never replaces, ongoing clinical care.
Safety Exclusion Criteria: This test is not suitable as a first‑line screen for acute metabolic decompensation; it requires pre‑test genetic counselling. Red‑flag symptoms (recurrent hypoglycaemia, jaundice, coagulopathy) warrant immediate emergency evaluation, not a genetic test.
Frequently Asked Questions
1. What does the EIF2AK3 gene test detect and how reliable is it?
Snippet‑grade answer: The test detects pathogenic variants in the entire EIF2AK3 gene with 99.9% analytical sensitivity, confirming Wolcott‑Rallison syndrome.
إجابة مختصرة: يكشف التحليل عن الطفرات المسببة للمرض في جين EIF2AK3 بحساسية تحليلية تبلغ 99.9%، مما يؤكد تشخيص متلازمة والكوت‑راليسون.
2. Why choose a single‑gene NGS test instead of whole exome sequencing?
Snippet‑grade answer: Single‑gene NGS provides deeper coverage of EIF2AK3, eliminates incidental findings, and delivers a faster, cost‑effective result at 2,800 AED.
إجابة مختصرة: يوفر تسلسل الجين الواحد تغطية أعمق لجين EIF2AK3 ويمنع النتائج العرضية، مع نتيجة أسرع وفعالة من حيث التكلفة (2800 درهم).
3. Is this test approved for children and does it comply with UAE laws?
Snippet‑grade answer: Yes, the test is performed under strict CDS Law 2026 minors’ consent protocols and Federal Decree‑Law No. 41 of 2024 (Art. 87) for genetic data protection.
إجابة مختصرة: نعم، يُجرى الاختبار وفقًا لبروتوكولات قانون CDS 2026 للموافقة على القُصّر والمرسوم الاتحادي رقم 41 لسنة 2024 بشأن حماية البيانات الجينية.
✔ UAE Healthcare Compliance:
- Licensed by MOHAP / DHA (Facility License: 9834453).
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) – all processes audited.
- Genetic testing adheres to UAE PDPL, Federal Decree‑Law No. 41 of 2024 (Art. 87), and CDS minors’ consent 2026.
- Paired with mandatory pre‑test genetic counselling and post‑ tele‑consultation.
For immediate insurance verification or home collection booking, WhatsApp: +971 54 548 8731
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians